It would be almost impossible to find a better example of the difficulties that face the pharmaceutical industry than the campaign against hepatitis C.
Called The Silent Killer, the blood-borne disease infects the liver, gradually doing irreversible damage over a two- to three-decade period. Most people who are infected do not even know this until symptoms of liver failure show up, at which time the disease can be life threatening. The majority of liver transplants in the U.S. are due to liver failure caused by long-term hepatitis C infection.
